For glutamine-expansion disorders, peptide nucleic acid (PNA) and locked nucleic acid (LNA) antisense oligomers targeting CAG repeats have been used to reduce expanded HD and SCA3 transcripts in vitro[36]–[39]. The gene discussed is ATXN3; the disease is Huntington disease.